Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulation… Read more
Market Cap & Net Worth: Canntab Therapeutics Limited (CTABF)
Canntab Therapeutics Limited (PINK:CTABF) has a market capitalization of $3.89K ($3.89K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46403 globally and #14461 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Canntab Therapeutics Limited's stock price $0.00 by its total outstanding shares 38909159 (38.91 Million).
Canntab Therapeutics Limited Market Cap History: 2017 to 2025
Canntab Therapeutics Limited's market capitalization history from 2017 to 2025. Data shows change from $25.84 Billion to $3.89K (-89.21% CAGR).
Canntab Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Canntab Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.19x
Canntab Therapeutics Limited's market cap is 1.19 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $25.84 Billion | $942.36K | -$1.12 Million | 27416.08x | N/A |
| 2018 | $27.78 Million | $26.67K | -$2.41 Million | 1041.78x | N/A |
| 2019 | $16.65 Million | $240.00K | -$2.46 Million | 69.37x | N/A |
| 2020 | $25.13 Million | $133.33K | -$2.61 Million | 188.48x | N/A |
| 2022 | $350.18K | $293.36K | -$3.69 Million | 1.19x | N/A |
Competitor Companies of CTABF by Market Capitalization
Companies near Canntab Therapeutics Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Canntab Therapeutics Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Canntab Therapeutics Limited Historical Marketcap From 2017 to 2025
Between 2017 and today, Canntab Therapeutics Limited's market cap moved from $25.84 Billion to $ 3.89K, with a yearly change of -89.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.89K | 0.00% |
| 2024 | $3.89K | -98.90% |
| 2023 | $354.07K | +1.11% |
| 2022 | $350.18K | -98.20% |
| 2021 | $19.45 Million | -22.59% |
| 2020 | $25.13 Million | +50.95% |
| 2019 | $16.65 Million | -40.07% |
| 2018 | $27.78 Million | -99.89% |
| 2017 | $25.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Canntab Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.89K USD |
| MoneyControl | $3.89K USD |
| MarketWatch | $3.89K USD |
| marketcap.company | $3.89K USD |
| Reuters | $3.89K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.